AMINOSYN-HBC 7% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for AMINOSYN-HBC 7% IN PLASTIC CONTAINER (AMINOSYN-HBC 7% IN PLASTIC CONTAINER).
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
| Metabolism | Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle; branched-chain amino acids (leucine, isoleucine, valine) are metabolized extrahepatically in skeletal muscle. |
| Excretion | Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination. |
| Half-life | Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand. |
| Protein binding | Amino acids are not significantly protein-bound; less than 10% bind to plasma proteins. |
| Volume of Distribution | Vd approximately 0.25-0.5 L/kg, reflecting distribution into total body water and lean body mass. |
| Bioavailability | Intravenous: 100% bioavailability. Not administered via other routes. |
| Onset of Action | Intravenous: Immediate upon infusion, typically within minutes as amino acids enter the systemic circulation. |
| Duration of Action | Intravenous: 2-4 hours post-infusion, depending on infusion rate and metabolic utilization; clinical effect (improved nitrogen balance) lasts while infusion continues. |
| Molecular Weight | 150 |
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal failure (eGFR < 25 mL/min/1.73 m²) unless dialysis; reduce dose by 50% for eGFR 25-50 mL/min/1.73 m². |
| Liver impairment | Contraindicated in decompensated cirrhosis (Child-Pugh class C); use with caution in class B with dose reduction by 50%. |
| Pediatric use | 2-3 g amino acids/kg/day intravenously for children; weight-based infusion rate: 0.1-0.15 g/kg/h. |
| Geriatric use | Start at lower end of adult dosing (1 L/day) and monitor fluid balance due to reduced renal function; adjust based on eGFR. |
| 1st trimester | Aminosyn-HBC 7% is an amino acid solution used in parenteral nutrition. Safety in first trimester not established; use only if clearly needed and benefit outweighs risk. Maternal malnutrition may harm fetus, but specific teratogenic risks unknown. |
| 2nd trimester | Limited data; use with caution. Parenteral nutrition may be necessary for maternal health. Monitor for fluid and electrolyte imbalances. |
| 3rd trimester | Generally considered safer if maternal nutrition is critical. May be used under medical supervision. Avoid if contraindicated conditions exist. |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN-HBC 7% IN PLASTIC CONTAINER (AMINOSYN-HBC 7% IN PLASTIC CONTAINER).
| Placental transfer | Amino acids are actively transported across placenta. Degree of transfer depends on maternal levels and fetal needs. Exogenous administration may alter fetal amino acid profile; clinical significance unknown. |
| Breastfeeding | Excretion into breast milk is unknown. Parenteral amino acids are unlikely to reach significant levels in milk due to rapid metabolism. Caution in lactating women; consider benefits of breastfeeding vs. potential risks. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No known teratogenic risk. AMINOSYN-HBC 7% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. It should be used during pregnancy only if clearly needed. |
| Fetal Monitoring | Monitor maternal fluid balance, electrolytes, acid-base status, blood glucose, and renal function. For the fetus, monitor growth and well-being via ultrasound and fetal heart rate as clinically indicated, especially if maternal metabolic complications arise. |
| Fertility Effects | No known effects on fertility. There are no studies on reproductive performance in animals or humans with this product. |
■ FDA Black Box Warning
None.
| Serious Effects |
Severe electrolyte disordersAcid-base imbalanceHepatic coma or severe hepatic insufficiencySevere renal impairment (unless dialysis)Hypersensitivity to any componentInborn errors of amino acid metabolism
| Precautions | Monitor for signs of hyperammonemia, electrolyte imbalances, and volume overload., Use with caution in patients with renal impairment, metabolic acidosis, or phenylketonuria., Risk of infection from intravenous catheter use. |
| Food/Dietary | Administered intravenously, no direct food interactions. However, oral intake should be restricted as per clinical condition (e.g., low-protein diet in hepatic encephalopathy). |
| Clinical Pearls | AMINOSYN-HBC 7% is a high branched-chain amino acid (BCAA) formulation intended for parenteral nutrition in patients with hepatic encephalopathy or severe liver disease. It should be used with caution in patients with renal impairment due to risk of hyperazotemia. Monitor serum electrolytes, ammonia, and liver function tests closely. Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis. |
| Patient Advice | This medication is given intravenously and contains amino acids to provide nutrition when you cannot eat. · Report any signs of infection at the IV site, such as redness, swelling, or pain. · Notify your healthcare provider if you experience nausea, vomiting, headache, or confusion. · Your blood sugar and electrolyte levels will be monitored regularly during treatment. · This solution is specifically formulated for liver problems; do not share or use it for other purposes. |
Loading safety data…